vTv Therapeutics to Participate in 7th Annual Evercore HealthCONx Conference
vTv Therapeutics (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on novel small molecules and diabetes treatments, has announced its participation in the 7th Annual Evercore HealthCONx Conference in Coral Gables, Florida. The company's management will engage in a fireside chat and one-on-one meetings during the event, scheduled for December 3-5, 2024.
The presentation is set for December 4, 2024, from 7:55 to 8:15 AM ET. Interested parties can access a live webcast through the Events section of vTv's investor relations website. Meeting requests can be made through institutional contacts.
vTv Therapeutics (Nasdaq: VTVT), una società biofarmaceutica in fase clinica focalizzata su nuove piccole molecole e trattamenti per il diabete, ha annunciato la sua partecipazione alla 7ª Annual Evercore HealthCONx Conference che si terrà a Coral Gables, Florida. La gestione dell'azienda parteciperà a una chiacchierata informale e a incontri individuali durante l'evento, previsto per il 3-5 dicembre 2024.
La presentazione è programmata per il 4 dicembre 2024, dalle 7:55 alle 8:15 AM ET. Le parti interessate possono accedere a una trasmissione in diretta attraverso la sezione Eventi del sito web delle relazioni con gli investitori di vTv. Le richieste di incontro possono essere effettuate tramite contatti istituzionali.
vTv Therapeutics (Nasdaq: VTVT), una empresa biofarmacéutica en fase clínica centrada en nuevas pequeñas moléculas y tratamientos para la diabetes, ha anunciado su participación en la 7ª Conferencia Anual Evercore HealthCONx en Coral Gables, Florida. La dirección de la empresa participará en un chat informal y en reuniones uno a uno durante el evento, programado para el 3 al 5 de diciembre de 2024.
La presentación está programada para el 4 de diciembre de 2024, de 7:55 a 8:15 AM ET. Las partes interesadas pueden acceder a una transmisión en vivo a través de la sección de Eventos del sitio web de relaciones con inversores de vTv. Las solicitudes de reunión pueden hacerse a través de contactos institucionales.
vTv Therapeutics (Nasdaq: VTVT)는 새로운 소분자 및 당뇨병 치료에 집중하는 임상 단계의 생물 제약 회사로, 플로리다 주 코랄 게이블스에서 열리는 제7회 연례 Evercore HealthCONx 컨퍼런스에 참여한다고 발표했습니다. 회사 경영진은 2024년 12월 3일부터 5일까지 예정된 행사에서 화기애애한 대화와 일대일 미팅에 참여할 예정입니다.
발표는 2024년 12월 4일 오전 7:55분부터 8:15분(ET)까지 진행됩니다. 관심이 있는 분들은 vTv의 투자자 관계 웹사이트의 이벤트 섹션을 통해 실시간 웹캐스트에 액세스할 수 있습니다. 회의 요청은 기관 연락처를 통해 할 수 있습니다.
vTv Therapeutics (Nasdaq: VTVT), une entreprise biopharmaceutique en phase clinique axée sur de nouvelles petites molécules et des traitements pour le diabète, a annoncé sa participation à la 7ème Conférence Annuelle Evercore HealthCONx à Coral Gables, en Floride. La direction de l'entreprise participera à un dialogue informel et à des réunions individuelles durant l'événement, prévu du 3 au 5 décembre 2024.
La présentation est prévue pour le 4 décembre 2024, de 7h55 à 8h15 (ET). Les parties intéressées peuvent accéder à un webinaire en direct via la section Événements du site des relations avec les investisseurs de vTv. Les demandes de réunion peuvent être faites par le biais de contacts institutionnels.
vTv Therapeutics (Nasdaq: VTVT), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf neuartige kleine Moleküle und Diabetesbehandlungen konzentriert, hat seine Teilnahme an der 7. jährlichen Evercore HealthCONx-Konferenz in Coral Gables, Florida, angekündigt. Das Management des Unternehmens wird während der Veranstaltung, die für den 3. bis 5. Dezember 2024 geplant ist, an einem informellen Gespräch und persönlichen Meetings teilnehmen.
Die Präsentation ist für den 4. Dezember 2024, von 7:55 bis 8:15 Uhr ET, angesetzt. Interessierte Parteien können über den Veranstaltungsbereich der Investor-Relations-Website von vTv auf einen Live-Webcast zugreifen. Meeting-Anfragen können über institutionelle Kontakte gestellt werden.
- None.
- None.
HIGH POINT, N.C., Dec. 02, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company with a portfolio of novel small molecules and a lead program in diabetes, today announced that management will participate in a fireside chat and be available for one-on-one meetings at the 7th Annual Evercore HealthCONx Conference to be held in Coral Gables. Florida, December 3 – 5, 2024.
| 7th Annual Evercore HealthCONx Conference | |
| Presentation Date: | December 4, 2024 |
| Time: | 7:55 – 8:15 AM ET |
| Webcast Link: | click here |
A live webcast of the presentation will be available via the Events section of the Company’s investor relations website at https://ir.vtvtherapeutics.com/events.
To request a meeting or for more details about the conference please reach out to your institutional contact or email.
About vTv Therapeutics
vTv Therapeutics Inc. is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates. vTv's clinical pipeline is led by cadisegliatin, a potential adjunctive therapy to insulin for the treatment of type 1 diabetes. vTv and its development partners are investigating additional indications including type 2 diabetes and other chronic conditions.
Forward-Looking Statement
This release contains forward-looking statements, which involve risks and uncertainties. These forward- looking statements can be identified by the use of forward-looking terminology, including the terms “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and, in each case, their negative or other various or comparable terminology. All statements other than statements of historical facts contained in this release, including statements regarding the timing of our clinical trials, our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause our results to vary from expectations include those described under the heading “Risk Factors” in our Annual Report on Form 10-K and our other filings with the SEC. These forward-looking statements reflect our views with respect to future events as of the date of this release and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. These forward-looking statements represent our estimates and assumptions only as of the date of this release and, except as required by law, we undertake no obligation to update or review publicly any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this release. We anticipate that subsequent events and developments will cause our views to change. Our forward-looking statements do not reflect the potential impact of any future acquisitions, merger, dispositions, joint ventures, or investments we may undertake. We qualify all of our forward-looking statements by these cautionary statements.
Contact
Ashley Robinson LifeSci Advisors, LLC
arr@lifesciadvisors.com
FAQ
When is vTv Therapeutics (VTVT) presenting at the Evercore HealthCONx Conference 2024?
Where can I watch vTv Therapeutics' (VTVT) Evercore HealthCONx Conference presentation?
What type of participation will VTVT have at the 2024 Evercore HealthCONx Conference?
Where is the 7th Annual Evercore HealthCONx Conference being held for VTVT's presentation?
